- ClearPoint Neuro Inc’s (NASDAQ:CLPT) Swedish partner, Clinical Laserthermia Systems (CLS), has received FDA 510(k) clearance for its laser, which the company plans to commercialize as the ClearPoint Prism Neuro Laser Therapy System.
- The ClearPoint Prism Neuro Laser Therapy System is indicated for use to necrotize or coagulate soft tissue through interstitial irradiation or thermal therapy under 3.0T magnetic resonance imaging (MRI) guidance.
- Related: FDA Approves ClearPoint Neuro’s Updated Software For Guidance System For Neurological Procedures.
- ClearPoint Neuro has exclusive global rights to commercialize the CLS magnetic resonance (MR) guided laser interstitial thermal therapy (MRgLITT) system for neuro applications.
- The system comprises a clinical solution combining the ClearPoint navigation platform, the laser technology from CLS, and a thermal ablation monitoring software, Thermoguide from France-based medical device company Image Guided Therapy SA (IGT).
- The ClearPoint Prism Neuro Laser Therapy System is currently in limited market release at select academic medical centers across the U.S.
- Price Action: CLPT shares are up 8.21% at $10.94 during the premarket session on the last check Friday.
Dogecoin Rises More Than 3% In 24 hours
Over the past 24 hours, Dogecoin's (CRYPTO: DOGE) price has risen 3.37% to $0.09. This is contrary to its negative trend over the past week where it has experienced a 0.0% loss, moving from $0.09 to its current price. As it stands right now, the coin's all-time high is $0.73.
